Splenectomy in Hodgkin's Disease for splenomegaly, cytopenias and intolerance to myelosuppressive chemotherapy.
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000209:etiology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001772:Blood Cell Count; D001855:Bone Marrow Diseases / Q000150:complications; D001856:Bone Marrow Examination; D005260:Female; D006400:Hematocrit; D006689:Hodgkin Disease / Q000150:complications*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007970:Leukopenia / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects; D009929:Organ Size; D011241:Prednisone / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects*; D012156:Reticulocytes; D013156:Splenectomy; D013163:Splenomegaly / Q000209:etiology*; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*; D014747:Vinblastine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D009588:Nitrogen Mustard Compounds; D014750:Vincristine; D014747:Vinblastine; D011241:Prednisone